Search research articles
Contact Us
Filters
Showing results (51-60 of 84) with videos related to
Page
of 9
Sort By:
Cancer Chemotherapy and Pharmacology
|
May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
Tara L Lin, Laura F Newell, Robert K Stuart, et al.
Blood Neoplasia
|
September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML
Vinod A Pullarkat, Mark Levis, James McCloskey, et al.
Blood Advances
|
March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
Tara L Lin, David A Rizzieri, Daniel H Ryan, et al.
JNCI Cancer Spectrum
|
July 19, 2023
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations
Thomas J George, Tara L Lin, Tricia Adrales Bentz, et al.
NPJ Precision Oncology
|
January 19, 2022
Functional characterization of NPM1-TYK2 fusion oncogene
Sudhakiranmayi Kuravi, Riley W Baker, Muhammad Umair Mushtaq, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2020
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression
Alison R Walker, John C Byrd, James S Blachly, et al.
Blood
|
October 21, 2016
Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation
Omar S Aljitawi, Soumen Paul, Avishek Ganguly, et al.
The Lancet. Haematology
|
June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Blood Advances
|
February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial
Shai Shimony, H Moses Murdock, Julia H Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 84) with videos related to
Sort By:
Page
of 9
Cancer Chemotherapy and Pharmacology
|
May 18, 2019
A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias
Tara L Lin, Laura F Newell, Robert K Stuart, et al.
Blood Neoplasia
|
September 11, 2025
V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML
Vinod A Pullarkat, Mark Levis, James McCloskey, et al.
Blood Advances
|
March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses
Tara L Lin, David A Rizzieri, Daniel H Ryan, et al.
JNCI Cancer Spectrum
|
July 19, 2023
Quantifying the impact of the COVID-19 pandemic on cancer center clinical trial operations
Thomas J George, Tara L Lin, Tricia Adrales Bentz, et al.
NPJ Precision Oncology
|
January 19, 2022
Functional characterization of NPM1-TYK2 fusion oncogene
Sudhakiranmayi Kuravi, Riley W Baker, Muhammad Umair Mushtaq, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 22, 2020
Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of <i>HOXA9</i> and <i>MEIS1</i> Expression
Alison R Walker, John C Byrd, James S Blachly, et al.
Blood
|
October 21, 2016
Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation
Omar S Aljitawi, Soumen Paul, Avishek Ganguly, et al.
The Lancet. Haematology
|
June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
Jeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Blood Advances
|
February 2, 2026
CPX-351 Selectively Benefits Patients with AML and Myelodysplasia-Related Mutations in the Pivotal Randomized Trial
Shai Shimony, H Moses Murdock, Julia H Keating, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H Wei, Stephen A Strickland, Jing-Zhou Hou, et al.
Page
of 9